Insights from investigating the interactions of natural product inhibitors with neuraminidase of the 2009 H1N1 influenza virus

doi:10.5246/jcps.2020.06.037

Abstract

Abstract:

Neuraminidase (NA) plays a biologically vital role in the replication of influenza virus, and NA inhibitors (NAIs) are most widely used in the clinical anti-flu therapy. NA of 2009 H1N1 influenza virus (09N1) possesses a different substrate-binding cavity compared with other NA subtypes, making 09N1 a more appropriate starting point for the discovery of potent 09N1 inhibitors. As natural products are of great structural diversity, research on the interaction between natural NAIs and 09N1 can throw light on the design of new structural NAIs. In this study, we, for the first time, conducted molecular docking procedure with GOLD on 10 natural inhibitors to 09N1, and acquired their binding modes with 09N1. The docking results showed that the active site S1 was important in the binding of NAIs to 09N1. Then five scaffolds were extracted from these NAIs with interactions to site S1, and these could be used in the structural modification of NAIs. Besides, we found that the addition of H-bonding interaction with the active site could improve the NA inhibitory activity of NAIs, and it might be the reason why the approved NAIs showed high efficiency. Two terminal hydrophobic sites (Terminal 1 and Terminal 2) with no interactions to the approved NAI zanamivir were found in the 09N1 active cavity, and four NAIs were first found to bind with the terminals. Till now, there are few studies on the meaning of Terminal 2 in the binding of NAI to NA, which could be a new direction for the rational design of NAIs.

Key words: 2009 H1N1 influenza virus, Neuraminidase, Inhibitor, Natural product, Molecular docking

CLC Number:

R914.2

Supporting:

Yurui Jin, Aixiu Li, Jiaxiong Kang. Insights from investigating the interactions of natural product inhibitors with neuraminidase of the 2009 H1N1 influenza virus[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(6): 390-397.

References

[1] Colman, P.M.; Varghese, J.N.; Laver, W.G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983, 303, 41-44.

[2] Russell, R.J.; Haire, L.F.; Stevens, D.J.; Collins, P.J.; Lin, Y.P.; Blackburn, G.M.; Hay, A.J.; Gamblin, S.J.; Skehel, J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006, 443, 45-49.

[3] Li, Q.; Qi, J.X.; Zhang, W.; Vavricka, C.J.; Shi, Y.; Wei, J.H.; Feng, E.G.; Shen, J.S.; Chen, J.L.; Liu, D.; He, J.H.; Yan, J.H.; Liu, H.; Jiang, H.L.; Teng, M.K.; Li, X.B.; Gao, G.F. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat. Struct. Mol. Biol. 2010, 17, 1266-1268.

[4] Lee, N.; Hurt, A.C. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr. Opin. Infect. Dis. 2018, 31, 520-526.

[5] Stoll, V.; Stewart, K.D.; Maring, C.J.; Muchmore, S.; Giranda, V.; Gu, Y.G.; Wang, G.; Chen, Y.W.; Sun, M.H.; Zhao, C.; Kennedy, A.L.; Madigan, D.L.; Xu, Y.B.; Saldivar, A.; Kati, W.; Laver, G.; Sowin, T.; Sham, H.L.; Greer, J.; Kempf, D. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Biochemistry. 2003, 42, 718-727.

[6] Grienke, U.; Schmidtke, M.; Kirchmair, J.; Pfarr, K.; Wutzler, P.; Dürrwald, R.; Wolber, G.; Liedl, K.R.; Stuppner, H.; Rollinger, J.M. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J. Med. Chem. 2010, 53, 778-786.

[7] Amaro, R.E.; Minh, D.D.; Cheng, L.S.; Lindstrom, W.M. Jr, Olson, A.J.; Lin, J.H.; Li, W.W.; McCammon, J.A. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J. Am. Chem. Soc. 2007, 129, 7764-7765.

[8] Wang, M.Y.; Qi, J.X.; Liu, Y.; Vavricka, C.J.; Wu, Y.; Li, Q.; Gao, G.F. Influenza A virus N5 neuraminidase has an extended 150-cavity. J. Virol. 2011, 85, 8431-8435.

[9] Rudrawar, S.; Dyason, J.C.; Rameix-Welti, M.A.; Rose, F.J.; Kerry, P.S.; Russell, R.J.; van der Werf, S.; Thomson, R.J.; Naffakh, N.; von Itzstein, M. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat. Commun. 2010, 1, 113.

[10] Feng, E.G.; Shin, W.J.; Zhu, X.L.; Li, J.; Ye, D.J.; Wang, J.; Zheng, M.Y.; Zuo, J.P.; No, K.T.; Liu, X.; Zhu, W.L.; Tang, W.; Seong, B.L.; Jiang, H.L.; Liu, H. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. J. Med. Chem. 2013, 56, 671-684.

[11] Singh, N.; Anjum, N.; Chandra, R. Combating influenza: natural products as neuraminidase inhibitors. Phytochem. Rev. 2019, 18, 69-107.

[12] Kirchmair, J.; Rollinger, J.M.; Liedl, K.R.; Seidel, N.; Krumbholz, A.; Schmidtke, M. Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. Future Med. Chem. 2011, 3, 437-450.

[13] Dao, T.T.; Nguyen, P.H.; Lee, H.S.; Kim, E.; Park, J.; Lim, S.I.; Oh, W.K. Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. Bioorg. Med. Chem. Lett. 2011, 21, 294-298.

[14] Dao, T.T.; Nguyen, P.H.; Won, H.K.; Kim, E.H.; Park, J.; Won, B.Y.; Oh, W.K. Curcuminoids from Curcuma longa and their inhibitory activities on influenza A neuraminidases. Food Chem. 2012, 134, 21-28.

[15] Jin, Y.; Li, A.; Deng, L.; Luo, L.; Li, K. Molecular docking study based on 2009 H1N1 influenza neuraminidase. Comput. Appl. Chem. 2014, 31, 298-302.